HRS-5965 capsule for primary IgA nephropathy

Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy

This Phase 3 trial will test whether HRS-5965 capsules reduce proteinuria and are safe for people with biopsy-confirmed primary IgA nephropathy who have persistent proteinuria and eGFR ≥30.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 378 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Chengdu Suncadia Medicine Co., Ltd. (Industry-sponsored)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07014826 on ClinicalTrials.gov

What this trial studies

This Phase 3, randomized, double-blind, parallel, placebo-controlled trial randomizes participants to HRS-5965 capsules or matching placebo while continuing optimized supportive therapy including RAS blockade. Eligible participants must have biopsy-confirmed primary IgA nephropathy (within 8 years), persistent proteinuria (24‑hour urine protein ≥1.0 g or UPCR ≥0.8 g/g), and eGFR ≥30 ml/min/1.73 m2. The study monitors efficacy and safety outcomes related to proteinuria and kidney function during the treatment period. Trial procedures, dosing, and duration are defined in the study protocol and managed at participating clinical sites.

Who should consider this trial

Good fit: Adults with biopsy-confirmed primary IgA nephropathy within 8 years, persistent proteinuria despite optimized RAS blocker therapy, weight ≥35 kg, BMI <37.5 kg/m2, and eGFR ≥30 ml/min/1.73 m2 are ideal candidates.

Not a fit: People with advanced kidney failure (eGFR <30), minimal or no proteinuria, unconfirmed IgA nephropathy, or those planning pregnancy or fertility procedures are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, HRS-5965 could lower proteinuria and help slow kidney function loss in people with primary IgA nephropathy.

How similar studies have performed: Other therapies that reduce proteinuria have improved outcomes in IgA nephropathy, but HRS-5965 appears to be a novel agent with limited publicly available Phase 3 results to date.

Eligibility criteria

Inclusion Criteria:

1. Able and willing to provide a written informed consent；
2. Weight ≥35 kg, Body mass index (BMI) \< 37.5kg /m2;
3. Primary IgA nephropathy was confirmed by renal biopsy within 8 years;
4. 24-UPE≥ 1.0g /24h, or 24-UPCR≥ 0.8g/g at screen, and 24-UPCR≥ 0.8g/g prior to randomization;
5. eGFR≥30 ml/min/1.73m2 at screening and prior to randomization; (CKD-EPI formula)
6. A fertile female subject or a male subject whose partner is a fertile female, who has not had a fertility, sperm/egg donation plan from the signing of the informed consent to 1 month after the last dose, and voluntarily takes effective contraceptive measures (including the partner);
7. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.
8. Receiving optimal supportive therapy including RAS blockers and stabilizing the dose for at least 12 weeks after reaching the maximum recommended dose or the maximum tolerated dose prior to randomization;

Exclusion Criteria:

1. Allergic to any RAS blockers, investigational products, or components as evaluated by the investigator;
2. Patients with secondary IgA nephropathy as determined by the investigator;
3. IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;
4. Patients with a history of immunodeficiency disease; Or in combination with other systemic diseases likely to cause proteinuria; Or with Nephrotic Syndrome;
5. Have any organ transplant;
6. Patients with active infection of tuberculosis within 1 year prior to screening, such as liver abscess and pyelonephritis; Or subjects with active infection who requiring intravenous antibiotic therapy within 2 weeks prior to randomization;
7. Patients with a history of malignant neoplasms;
8. Patients with a history of severe trauma or major surgery within 12 weeks prior to screening, or who plan to undergo surgery during the study period;
9. Patients with a history of blood donation or a history of severe blood loss (≥400 mL blood loss) within 12 weeks prior to screening, or who have received blood transfusions within 12 weeks prior to screening;
10. The presence of a disease or medical condition determined by the investigator might affect drug absorption, distribution, metabolism, and excretion;
11. As determined by the investigator, the subject has any of the following: progression or recovery of a disease;
12. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), or total bilirubin exceeding 3 times the upper limit of normal (ULN) at screening;
13. Participants who have participated in a clinical trial of any drug or medical device within 12 weeks prior to randomization and are expected to have residual effects of the investigational treatment (as determined by the investigator), or who were within the follow-up period of a clinical study, or within 5 half-lives of the investigational drug, or within 30 days (whichever is older) before screening;
14. Women who are pregnant or breastfeeding;
15. A history of drug abuse;
16. Participants who received systemic glucocorticoid or immune suppressants within 12 weeks prior to randomization and are expected to have during research；
17. Participants who received biologics or cytokine inhibitor within 6 months prior to randomization and are expected to have during research；
18. Any physical or mental illness or condition that, as determined by the investigator, is likely to increase the risk of the study, affect the subject's adherence to the protocol, or prevent the subject from completing the study.

Where this trial is running

Beijing, Beijing Municipality

• Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Sheng Qi

Conditions Primary IgA Nephropathy